Asthma Therapeutics Market In The Asia-Pacific Region Is Expected To Increase In Value At A CAGR Of 7.2%, To Become Over $5.6 Billion Till 2021

Researchmoz added Most up-to-date research on "Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns" to its huge collection of research reports.

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=686317

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

- What are the competitive advantages of the existing novel drugs?

With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/asthma-therapeutics-in-asiapacific-markets-to-2021-high-prevalence-and-launch-of-latestage-biologics-will-drive-the-market-in-spite-of-affordability-concerns-report.html/toc

Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

- Will affordability threaten the commercial success of existing drugs as well as newer biologics?
- Which of the assessed countries have affordability concerns?

Reasons to buy

This report will enable you to -
- Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
- Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=686317

Asthma And COPD Drugs Market Will Exhibit A 4.1% CAGR From 2016 Through 2024, Rising To A Valuation Of US$18.7 bn

Researchmoz added Most up-to-date research on "Asthma and COPD Drugs Market - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024" to its huge collection of research reports.

Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the WHO predicts that COPD will become the third most common cause of death globally by 2030. However, these statistics have already materialized in the U.S. and China, where COPD is currently said to be the third leading cause of mortality.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=893048

According to the Asthma and Allergy Foundation of America, asthma is the leading chronic disease in children in the U.S. It is also the most common reason for missed school days. Moreover, an estimated 10 people in the U.S. die from asthma each day, while 3,630 die each year. In China, the figures are worse. A large population of COPD patients goes underdiagnosed or misdiagnosed in China every year. A large proportion of these deaths are avoidable with proper treatment and care. Thus, the existence of an unmet medical need is clearly evident and is anticipated to augment the asthma and COPD drugs market.

U.S. and China Asthma and COPD Drugs Market: Scope and Methodology

This report on the asthma and COPD drugs market in the U.S. and China analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as technological developments, patent expiry, recent drug approvals, investment in clinical studies and acquisitions by leading players in the market, and historical year-on-year growth have been taken into consideration while estimating the market size.

Growth rates for each segment within the U.S. and China asthma and COPD drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, drug development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the asthma and COPD drugs market in the U.S and China.

Browse Detail Report With Full TOC @ http://www.researchmoz.us/asthma-and-copd-drugs-market-us-and-china-industry-analysis-size-share-growth-trends-and-forecast-2016-2024-report.html

U.S. and China Asthma and COPD Drugs Market: Segmentation

Based on drug class, the asthma and COPD drugs market in the U.S and China has been segmented into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. The bronchodilator class has been further segmented into short acting beta-2 agonists, long acting beta-2 agonists, and anti-cholinergic agents. The anti-inflammatory drug class has been further segmented into oral and inhaled corticosteroids, anti-leukotrienes, phosphodiesterase type 4 inhibitors, and others. The others segment includes mast cell stabilizers and other anti-inflammatory agents used in asthma and COPD control.

Based on indication, the asthma and COPD drugs market in the U.S. and China has been segmented into asthma and COPD. According to the CDC, one in 12 people in the U.S. has asthma, and the number is rising each year. Pollution in China is among the worst in the world. This is likely to worsen asthma and COPD symptoms, consequently driving the asthma and COPD market in China during the forecast period.

Geographically, the asthma and COPD market has been segmented into two countries: the U.S. and China. These countries have been further segmented by indication and drug class.

U.S. and China Asthma and COPD Drugs Market: Competitive Landscape

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the asthma and COPD drugs market in the U.S. and China. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include GlaxoSmithKline plc, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Boehringer Ingelheim, and Merck and Co., Inc.

The U.S. and China asthma and COPD drugs market has been segmented as follows:

U.S. and China Asthma and COPD Drugs Market, by Drug Class

Bronchodilators

- Short Acting Beta-2 Agonists
- Long Acting Beta-2 Agonists
- Anti-cholinergic Agents

Anti-inflammatory Drugs

- Oral and Inhaled Corticosteroids
- Anti-leukotrienes
- Phosphodiesterase Type-4 Inhibitors
- Others

Monoclonal Antibodies
Combination Drugs

U.S. and China Asthma and COPD Drugs Market, by Indication

- Asthma
- COPD

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=893048

Global Asthma & COPD Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2015

Researchmoz added Most up-to-date research on "Global Asthma & COPD Market Report: 2015 Edition" to its huge collection of research reports.

Asthma is a common chronic disease linking the airway in the lungs that affects the people of all age groups. The airways or bronchial tubes, allow air to come in and out of the lungs. The airway of asthmatic patients is generally inflamed and becomes swollen over time. This makes it difficult for air to move in and out of the lungs, causing symptoms such as coughing, wheezing, shortness of breath and/ or chest tightness.

The prevalence of asthma is expected to increase significantly in the coming years. The market for asthma drugs is driven by various factors including increasing global spending on medicines, increasing tobacco and cigarette consumption, rising prevalence of non-communicable diseases, more use of biologics, and increasing healthcare expenditure worldwide. The major upcoming trends in the asthma market include introduction of new severe asthma and Chronic Obstructive Pulmonary Disease (COPD) drugs, and introduction of new mechanisms that will help drive the market. However, there are certain challenges hindering the growth of the market. Such challenges include increased pricing pressures, patent expiries and introduction of generic drugs in the market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=363110

The market for asthma and COPD drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative asthma and COPD drugs and treatments. Further, the companies are combining businesses and spending comprehensively on research and development to develop effective treatment methods for asthma.

The present report provides a comprehensive analysis of the global asthma & COPD market with focus on regions like the U.S. and European Union. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include AstraZeneca, Merck and Co., Roche, Sanofi and Novartis which are also profiled in this report.

Table of Content

1. Overview1.1 Definition of Asthma   
1.2 Types of Asthma   
1.3 Triggers of Asthma   
1.4 Treatment Options for Asthma   
1.5 Chronic Obstructive Pulmonary Disease (COPD)
1.5.1 Difference between Asthma and COPD   
1.5.2 Treatment Options for COPD

2. Market Analysis
2.1 Global Respiratory Market   

    Market Value
    Market Segments
    Regional Breakdown

2.1.1 Global Respiratory Therapeutics Market   

    Market Value
    Product Segmentation

2.1.2 Global Inhalation Drug Delivery Technologies Market

    Market Value
    Product Segmentation

2.2 Global Asthma/COPD Market

    Market Value
    Prevalence Rate
    Regional Breakdown

2.2.1 Global Asthma/COPD Therapeutics Market
2.3 Global Severe Asthma Market

3. Regional Markets
3.1. The U.S.

    Market Overview
    Diagnosed/Treated Population

3.2 European Union

    Market Overview
    Diagnosed/Treated Population

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Global Spending on Medicines   
4.1.2 Cigarette and Tobacco Consumption   
4.1.3 Rising Prevalence of Non Communicable Diseases   
4.1.4 Increasing Use of Biologic Drugs   
4.1.5 Escalating Global GDP   
4.1.6 Global Healthcare Expenditure
4.2 Key Trends and Developments
4.2.1 Launch of New Severe Asthma Drugs   
4.2.2 Introduction of New COPD Drugs
4.3 Challenges
4.3.1 Increased Pricing Pressure
4.3.2 Patent Expiries and Generic Drugs

5. Competitive Landscape
5.1 Global Respiratory Market   
5.2 Global Severe Asthma Market

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=363110

U.S. and China Asthma and COPD Drugs Market Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024

Researchmoz added Most up-to-date research on "Asthma and COPD Drugs Market - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024" to its huge collection of research reports.

Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the WHO predicts that COPD will become the third most common cause of death globally by 2030. However, these statistics have already materialized in the U.S. and China, where COPD is currently said to be the third leading cause of mortality.

According to the Asthma and Allergy Foundation of America, asthma is the leading chronic disease in children in the U.S. It is also the most common reason for missed school days. Moreover, an estimated 10 people in the U.S. die from asthma each day, while 3,630 die each year. In China, the figures are worse. A large population of COPD patients goes underdiagnosed or misdiagnosed in China every year. A large proportion of these deaths are avoidable with proper treatment and care. Thus, the existence of an unmet medical need is clearly evident and is anticipated to augment the asthma and COPD drugs market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=893048

U.S. and China Asthma and COPD Drugs Market: Scope and Methodology

This report on the asthma and COPD drugs market in the U.S. and China analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as technological developments, patent expiry, recent drug approvals, investment in clinical studies and acquisitions by leading players in the market, and historical year-on-year growth have been taken into consideration while estimating the market size.

Growth rates for each segment within the U.S. and China asthma and COPD drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, drug development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the asthma and COPD drugs market in the U.S and China.

U.S. and China Asthma and COPD Drugs Market: Segmentation

Based on drug class, the asthma and COPD drugs market in the U.S and China has been segmented into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. The bronchodilator class has been further segmented into short acting beta-2 agonists, long acting beta-2 agonists, and anti-cholinergic agents. The anti-inflammatory drug class has been further segmented into oral and inhaled corticosteroids, anti-leukotrienes, phosphodiesterase type 4 inhibitors, and others. The others segment includes mast cell stabilizers and other anti-inflammatory agents used in asthma and COPD control.

Based on indication, the asthma and COPD drugs market in the U.S. and China has been segmented into asthma and COPD. According to the CDC, one in 12 people in the U.S. has asthma, and the number is rising each year. Pollution in China is among the worst in the world. This is likely to worsen asthma and COPD symptoms, consequently driving the asthma and COPD market in China during the forecast period.

Geographically, the asthma and COPD market has been segmented into two countries: the U.S. and China. These countries have been further segmented by indication and drug class.

U.S. and China Asthma and COPD Drugs Market: Competitive Landscape

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the asthma and COPD drugs market in the U.S. and China. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include GlaxoSmithKline plc, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Boehringer Ingelheim, and Merck and Co., Inc.

The U.S. and China asthma and COPD drugs market has been segmented as follows:

U.S. and China Asthma and COPD Drugs Market, by Drug Class

Bronchodilators
- Short Acting Beta-2 Agonists
- Long Acting Beta-2 Agonists
- Anti-cholinergic Agents

Anti-inflammatory Drugs

- Oral and Inhaled Corticosteroids
- Anti-leukotrienes
- Phosphodiesterase Type-4 Inhibitors
- Others

Monoclonal Antibodies
Combination Drugs

U.S. and China Asthma and COPD Drugs Market, by Indication

- Asthma
- COPD

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=893048

Asthma Therapeutics Market In The Asia-Pacific Region Is Expected To Increase In Value At A Compound Annual Growth Rate (CAGR) Of 7.2%, Over $5.6 Billion

Researchmoz added Most up-to-date research on "Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns" to its huge collection of research reports.

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=686317

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

- What are the competitive advantages of the existing novel drugs?

With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

- Will affordability threaten the commercial success of existing drugs as well as newer biologics?
- Which of the assessed countries have affordability concerns?

Reasons to buy

This report will enable you to -
- Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
- Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=686317

Asthma - Identifying and Commercializing First-in-Class Innovation | Latest Market Research Report

Researchmoz added Most up-to-date research on "Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports.

Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. GBI Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-in-class molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, despite the high clinical trial attrition rate, it is highly likely that many of the first-in-class technologies will reach the market over the coming decade and may transform the clinical and commercial landscape.

Biologics Growing in Prominence in Asthma Treatment

While the current asthma market is almost exclusively dominated by small molecules, which account for approximately 99% (the exception being Xolair), the current asthma pipeline includes 64 biologics, accounting for 24%. Small molecules amount to 178 compounds, equating to 66%.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=285641

This highlights both the commercial and clinical appeal of developing drugs of this class, and follows trends seen in other therapy areas, particularly oncology. Xolair (omalizumab), a recombinant humanized anti-IgE monoclonal Antibody (mAb), was the first humanized therapeutic mAb to be indicated for asthma. It was approved by the FDA in 2003 as an add-on therapy for adults and adolescents aged 12 and over, with moderate-to-severe allergic asthma and symptoms not adequately controlled with Inhaled Corticosteroids (ICS).

Xolair is also the only targeted therapy indicated for the treatment of a specific asthma phenotype. Its launch therefore addressed a significant unmet need for personalized therapy in asthma. Approximately 60% of asthmatics have allergic asthma, and may therefore benefit from Xolair treatment. However, only a minority of these patients has moderate-to-severe disease that is inadequately controlled with standard-of-care therapies, and is therefore eligible for treatment. Despite this, the drug has achieved blockbuster status, and although this can be attributed to a high Annual Cost of Therapy (ACoT), it is also reflective of how innovative drug development that targets unmet clinical needs can result in strong commercial outcomes. Indeed, drug developers are now looking to follow this example by developing highly specific biologics aimed at specific patient sub-types with the hope of benefiting previously underserved patients and generating strong revenues. Notable examples are mepolizumab, reslizumab, lebrikizumab and dupilumab, all of which target Interleukins (IL) heavily implicated in the inflammatory response.

A Deals Landscape with Numerous Investment Opportunities

Analysis has confirmed that 52 of the 59 first-in-class products have not been involved in a licensing or co-development deal. Although a number act on targets that are not yet strongly substantiated in terms of their therapeutic potential in asthma in clinical studies, many are supported by promising in vivo and in vitro preclinical evidence, and as such are highly promising asthma therapies. Indeed, breakthrough innovations are highly desirable as an investment option.

However, many deals involving first-in-class products were in early-stage development, whereas advance-in-class and addition-to-class product deals were typically made in late-stage development, indicating significant differentiation. These findings have significant strategic implications for both biotech companies seeking to out-license products and firms with an interest in in-licensing first-in-class products with strong clinical and commercial prospects.

Scope

- The report analyzes innovation in asthma in the context of the overall pipeline and the current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in asthma, and pinpoints opportunities for in-licensing. The report covers and includes
- A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms
- The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline
- Comprehensive review of the pipeline for first-in-class therapies, analyzed by of stage of development, molecule type, and molecular target
- Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
- Assessment of the licensing and co-development deal landscape for asthma therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products

Reasons to buy

- The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to
- Understand the focal shifts in molecular targets in the asthma pipeline
- Understand the distribution of pipeline programs by phase of development, molecule type and molecular target
- Access a scientific and clinical analysis of first-in-class developmental programs for asthma, benchmarked against non-first-in-class targets
- Access a list of the first-in-class therapies potentially open to deal-making opportunities

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=285641